As a formidable and known nucleoside analogue, Telbivudine is one of a few oral treatments to combat HBeAg positive and negative chronic hepatitis B. Known as the brand name Tyzeka, Telbivudine has a patent expiration of August 10, 2019. While the use of Telbivudine has been extremely successful in the United States, other countries around[…]
Telbivudine Makes Headlines in China for the Treatment of Hepatitis B
Antiviral, Patent Expiration 2019 Tags: Chinachronic hepatitis B Nov 05, 2013
Lamivudine Is Still a Formidable Treatment for HIV and HBV
Anti-Retroviral / Anti-HIV, Antiviral, Patent Expiration 2016 Tags: antiretroviral therapychronic hepatitis BHIV virus Nov 12, 2012
Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]
Entecavir Versus a Staggering Number of Hepatitis B Cases Worldwide
Antiviral, Patent Expiration 2015 Tags: CDCchronic hepatitis B Aug 03, 2012
Entecavir, CAS# 209216-23-9 may also be known by it’s brand name Baraclude. With the patent for Bristol-Myers Squibb’s Baraclude expiring on February 21, 2015, entecavir is on track to becoming a profitable generic product. Used to treat patients with chronic hepatitis B, entecavir is considered an antiviral medication. With a staggering 2 billion people around[…]
Adefovir Dipivoxil Effective Treatment for Patients with Chronic Hepatitis B
Anti-Retroviral / Anti-HIV, Drug Research & Development API Tags: chronic hepatitis BGilead Apr 30, 2012
Adefovir dipivoxil, CAS number 142340-99-6, is a nucleotide analog reverse transcriptase inhibitor, or “ntRTI”. Previously called bis-POM PMEA, adefovir dipivoxil is used is the treatment of chronic hepatitis B. Also produced under the trade names Hepsera and Preveon, adefovir dipivoxil is approved by the FDA for treatment in patients with active cases of chronic hepatitis[…]